Create a narrative

Piramal Pharma Community

NSEI:PPLPHARMA Community

1 Narratives written by author
0 Comments on narratives written by author
9 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 10 Analysts

CDMO And Inhalation Anesthesia Expansion Will Strengthen Future Prospects

Key Takeaways Innovation and on-patent manufacturing in CDMO business are set to drive future revenue and improve EBITDA margins through operating leverage. Expansion in inhalation anesthesia and investment in India Consumer Healthcare fuel growth, while cost optimization and sustainability initiatives enhance margins.

₹296.00

FV

30.4% undervalued

12.83%

Revenue growth p.a.

0

0

6

8 days ago